Spectranetics Refocuses On CLI Indication After PELA Submission Setback
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics is considering whether to continue to pursue a claudication indication for its CVX-300 excimer laser in light of disappointing peripheral excimer laser angioplasty (PELA) trial results